Literature DB >> 22837802

A rare case of acquired hemophilia A associated with myelodysplastic syndrome.

Mihir Raval, Rekha Kallamadi, Dinesh Bande.   

Abstract

84 year old male with past medical history of myelodysplastic syndrome (MDS) presented with progressive subcutaneous and muscle bleed in the right forearm and arm. Workup revealed elevated activated partial thromboplastin time (aPTT) - 71.8 seconds (normal 23 - 32 seconds) which was persistently elevated after mixing study (37.1 seconds immediately and 51.1 seconds after 1 hour). Further laboratory work up revealed low factor VIII level (3%) and elevated factor VIII inhibitor by Bethesda assay (3 units/ml of blood). Acquired hemophilia A (AHA) diagnosis was established and patient was treated with recombinant factor VIIa (rFVlla) to control the bleeding and also prednisone for immunosuppression. Subsequent monitoring suggested reduction of factor VIII inhibitor - antibody levels to undetectable level in 3 days and increase of factor VIII level from 3% to 50% in 5 days. Despite of improvement in the laboratory values he continued to have progression of his bleeding which involved posterior chest wall and also left arm. Due to the progression of the condition and prior expressed wish family decided to stop the aggressive treatment and patient died nine days after the diagnosis. The case report describes a rare presentation of AHA in MDS (With bone marrow cytogenetics abnormality) patient with fatal outcome.

Entities:  

Keywords:  Factor VIII; aPTT; acquired hemophilia A; bethesda assay; factor VIII inhibitor; myelodysplastic syndrome; rFVIIa

Year:  2012        PMID: 22837802      PMCID: PMC3403557     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  15 in total

1.  Acquired factor VIII inhibitor in association with myelodisplastic syndrome: report of a new case.

Authors:  Roberto Castelli; Alessio Faricciotti; Silvano Cicuti; Ferruccio Franceschini; Alessandro Vismara; Tomaso Porro
Journal:  Haematologica       Date:  2002-01       Impact factor: 9.941

2.  Failure of recombinant FVIIa as treatment for abdominal bleeding in acquired hemophilia.

Authors:  M Makris; K K Hampton; E E Preston
Journal:  Am J Hematol       Date:  2001-01       Impact factor: 10.047

Review 3.  Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.

Authors:  Julio Delgado; Victor Jimenez-Yuste; Fernando Hernandez-Navarro; Ana Villar
Journal:  Br J Haematol       Date:  2003-04       Impact factor: 6.998

4.  Proceedings: A more uniform measurement of factor VIII inhibitors.

Authors:  C K Kasper; L Aledort; D Aronson; R Counts; J R Edson; J van Eys; J Fratantoni; D Green; J Hampton; M Hilgartner; P Levine; J Lazerson; C McMillan; J Penner; S Shapiro; N R Shulman
Journal:  Thromb Diath Haemorrh       Date:  1975-11-15

Review 5.  Laboratory, clinical and therapeutic aspects of acquired hemophilia A.

Authors:  Massimo Franchini; Giovanni Targher; Martina Montagnana; Giuseppe Lippi
Journal:  Clin Chim Acta       Date:  2008-05-08       Impact factor: 3.786

Review 6.  Acquired hemophilia A: a concise review.

Authors:  Massimo Franchini; Giorgio Gandini; Tiziana Di Paolantonio; Guglielmo Mariani
Journal:  Am J Hematol       Date:  2005-09       Impact factor: 10.047

Review 7.  Acquired inhibitors.

Authors:  A J Cohen; C M Kessler
Journal:  Baillieres Clin Haematol       Date:  1996-06

8.  An acquired factor VIII inhibitor in association with a myeloproliferative/myelodysplastic disorder presenting with severe subcutaneous haemorrhage.

Authors:  T Biss; L Crossman; I Neilly; J Hanley
Journal:  Haemophilia       Date:  2003-09       Impact factor: 4.287

Review 9.  Dosing with recombinant factor viia based on current evidence.

Authors:  Ulla Hedner
Journal:  Semin Hematol       Date:  2004-01       Impact factor: 3.851

10.  International recommendations on the diagnosis and treatment of patients with acquired hemophilia A.

Authors:  Angela Huth-Kühne; Francesco Baudo; Peter Collins; Jørgen Ingerslev; Craig M Kessler; Hervé Lévesque; Maria Eva Mingot Castellano; Midori Shima; Jean St-Louis
Journal:  Haematologica       Date:  2009-04       Impact factor: 9.941

View more
  4 in total

1.  Feasibility of therapeutic plasma exchange-based combination therapy in the treatment of acquired hemophilia A: A retrospective 6 case series.

Authors:  Lin-Yue Wang; Yan Shen; Han-Qing Zeng; Ying Zhang; Shi-Feng Lou; Jian-Chuan Deng; Yun Luo
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

2.  Myelofibrosis and acquired hemophilia A: a case report.

Authors:  Marie Wrobel; Emilie Comio; Valerie Gay; Noureddine Baroudi; Pascal Meyer; Christine Chuniaud-Louche; Maya Hacini; Gian Matteo Pica
Journal:  J Med Case Rep       Date:  2016-05-07

Review 3.  Autoimmune Complications in Hematologic Neoplasms.

Authors:  Wilma Barcellini; Juri Alessandro Giannotta; Bruno Fattizzo
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

4.  Hemorrhagic pericardial effusion as the debut of acquired hemophilia in a chronic lymphocytic leukemia patient: A case report, and a review of acquired hemophilia A-related hematological malignancies.

Authors:  José María Bastida; María Teresa Cano-Mozo; Felix Lopez-Cadenas; Victor Eduardo Vallejo; Soraya Merchán; Cecilia Santos-Montón; David González-Calle; Javier Carrillo; Ana Africa Martín; Jose Angel Torres-Hernández; Marcos González; Francisco Martín-Herrero; Pedro Pabón; Jose Ramon González-Porras
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.